Hdac6 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Histone Deacetylase 6 | |
|---|---|
| Gene Symbol | HDAC6 |
| Full Name | Histone Deacetylase 6 |
| Chromosome | Xp11.23 |
| NCBI Gene ID | 10013 |
| OMIM | 300231 |
| Ensembl ID | ENSG00000094631 |
| UniProt ID | Q9UQR8 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, HD |
HDAC6 (Histone Deacetylase 6) is a unique Class IIb histone deacetylase primarily located in the cytoplasm, where it regulates protein acetylation, aggresome formation, and autophagy[^1]. Unlike other HDACs, HDAC6 predominantly targets non-histone proteins including Hsp90, tubulin, and cortactin.
HDAC6 has emerged as a promising therapeutic target in neurodegenerative diseases due to its role in protein quality control, aggresome formation, and autophagic clearance of misfolded proteins[^2].
HDAC6 encodes histone deacetylase 6, a unique class IIb HDAC primarily located in the cytoplasm. Unlike other HDACs, HDAC6 primarily deacetylates non-histone proteins including α-tubulin, HSP90, and cortactin. It plays critical roles in protein quality control, autophagy, and stress response.
Widely expressed with high levels in brain, liver, kidney, and heart. In brain, expressed in neurons and glia.
| Disease | Mechanism | References |
|---|---|---|
| Alzheimer's Disease | HDAC6 affects tau acetylation and clearance | [1] |
| Parkinson's Disease | HDAC6 protects against α-syn toxicity | [2] |
| ALS | HDAC6 regulates autophagy in motor neurons | [3] |
| Huntington's Disease | HDAC6 modulates mutant huntingtin clearance | [4] |
HDAC6-selective inhibitors are being developed for:
The study of Hdac6 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Simões-Pires, C., et al. (2013). HDAC6 as a target for neurodegenerative diseases. Current Alzheimer Research, 10(7), 705-720.
[2] Yan, J., et al. (2013). HDAC6 protects dopaminergic neurons. Journal of Neurochemistry, 127(6), 782-795.
[3] Brandherm, I., et al. (2020). HDAC6 in ALS. Acta Neuropathologica, 139(5), 687-704.
[4] Duan, W. (2013). Targeting HDAC6 for Huntington's disease. Expert Opinion on Therapeutic Targets, 17(9), 1015-1028.
HDAC6 (Histone Deacetylase 6) is a unique Class IIb HDAC primarily located in the cytoplasm. Unlike other HDACs, HDAC6 predominantly deacetylates non-histone substrates, including alpha-tubulin, HSP90, and cortactin. This makes HDAC6 a key regulator of cytoskeletal dynamics, protein folding, and stress responses.
HDAC6 is notable for its role in aggrephagy (selective autophagy of protein aggregates) and mitophagy (selective autophagy of damaged mitochondria). It interacts with ubiquitin and autophagy receptors to facilitate the clearance of toxic protein aggregates.
Alzheimer's Disease: HDAC6 modulates tau acetylation and aggregation. HDAC6 inhibitors reduce tau pathology in models. The protein also regulates amyloid-beta secretion and toxicity.
Parkinson's Disease: HDAC6 is involved in alpha-synuclein aggregation and clearance. HDAC6 inhibitors show neuroprotective effects in PD models by enhancing autophagy.
Huntington's Disease: HDAC6 regulates mutant huntingtin aggregation and clearance. HDAC6 inhibitors reduce pathology in HD models.
ALS: HDAC6 helps clear protein aggregates in ALS. HDAC6 activity may influence disease progression.
HDAC6 inhibitors (e.g., tubastatin A, ACY-1215) are being developed for neurodegenerative diseases. These compounds are generally better tolerated than pan-HDAC inhibitors. Benefits include improved autophagy, reduced protein aggregation, and neuroprotection.
HDAC6 is a promising target due to its cytoplasmic localization and disease-specific roles. Research focuses on developing selective inhibitors and understanding combination therapies with other approaches.
The field of epigenetics has emerged as a key area in understanding neurodegenerative diseases. DNA methylation patterns are dynamically regulated in the brain, and alterations in these patterns are increasingly recognized as contributors to disease pathogenesis.
Transgenic mouse models lacking DNMT3A in neural progenitor cells show altered brain development and behavior. These models are used to study the role of DNA methylation in neurodegeneration.
DNA methylation marks in peripheral tissues (blood, CSF) are being investigated as potential biomarkers for neurodegenerative disease diagnosis and progression.
Several clinical trials are exploring epigenetic therapies, including HDAC inhibitors and DNMT inhibitors, for neurodegenerative diseases. Early-phase trials have shown some promise.